Natera Dividend

Dividend criteria checks 0/6

Natera does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.8%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$3.60
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Aug 07

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

May 16

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Apr 18

Natera: Cracks In The Bearish Trade

Oct 10

Natera gains after publication of data on transplant rejection assessment test

Oct 04

Natera (NASDAQ:NTRA) Has Debt But No Earnings; Should You Worry?

Sep 13

Medicare extends coverage of Natera's Signatera test to muscle invasive bladder cancer

Jul 18

Nothing Compelling About Natera

Jun 24

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if NTRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTRA's dividend payments have been increasing.

Dividend Yield vs Market

Natera Dividend Yield vs Market

How does NTRA dividend yield compare to the market?
Segment	Dividend Yield
Company (NTRA)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.8%
Analyst forecast in 3 Years (NTRA)	0%

Notable Dividend: Unable to evaluate NTRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NTRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate NTRA's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NTRA has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Natera Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (Modern) A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer

Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?

Natera: Capitalizing On The Positive Momentum Of Personalized Medicine

Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™? in Stage II Colorectal Cancer

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 11%

Is Natera (NASDAQ:NTRA) A Risky Investment?

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 12% to US$86.94

Natera, Inc. Provides Earnings Guidance for the Year 2024

Natera, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Independent Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Natera, Inc. Announces New Study Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Provides Update on Ravgen Trial

Natera, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2023

Natera Announces New Study Highlighting the Benefits of Signatera's Unique Method of Quantifying ctDNA

Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)

Natera, Inc. Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Natera, Inc. Raises Revenue Guidance for the Full Year 2023

Is Natera (NASDAQ:NTRA) A Risky Investment?

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Natera, Inc. Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Natera's RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Announces Updated Data from the Galaxy Arm of the Circulate-Japan Trial

Natera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Natera, Inc. to Present New Signatera MRD Data At ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

Natera, Inc. Announces New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

Natera, Inc. Announces Senior Leadership Appointments

Natera, Inc. Announces Expanded I-Spy 2 Collaboration to Evaluate Signatera™? for Breast Cancer Patients in the Neoadjuvant Setting

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Co-Founder & Director notifies of intention to sell stock

Natera's Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Natera, Inc. Revises Earnings Guidance for the Year 2023

Natera Announces Completion of Enrollment to the Randomized, Phase III Altair Trial of Signatera in Colorectal Cancer

Co-Founder & Director notifies of intention to sell stock

United States District Court for the District of Delaware Issues Favorable Ruling for Natera, Inc. in False Advertising Trial Against CareDx, Inc

Natera, Inc.(NasdaqGS:NTRA) dropped from Russell 1000 Value Index

Natera, Inc. Announces Data from the ProActive Study that Supports Prospera™? Kidney as an Early Indicator of Transplant Rejection

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Natera, Inc. Raises Earnings Guidance for the Year 2023

Natera, Inc. Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

CEO, President & Director exercised options and sold US$140k worth of stock

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

CEO, President & Director exercised options and sold US$184k worth of stock

Consensus EPS estimates upgraded to US$4.08 loss

Chief Financial Officer exercised options and sold US$255k worth of stock

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Medicare Extends Coverage of Natera's Signatera(TM) MRD Test to Breast Cancer

Chief Financial Officer notifies of intention to sell stock

CEO, President & Director exercised options and sold US$223k worth of stock

Foundation Medicine, Inc. and Natera, Inc. Announce the Launch of FoundationOne Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use

CEO, President & Director exercised options and sold US$70k worth of stock

CEO, President & Director exercised options and sold US$72k worth of stock

Natera, Inc. Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers

Price target decreased to US$75.08

Natera, Inc. Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama NIPT

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $400.05 million.

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $400.05 million.

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Natera, Inc. Revises Earnings Guidance for the Year 2022

Natera, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Operating Officer exercised options and sold US$133k worth of stock

Chief Operating Officer exercised options and sold US$85k worth of stock

Natera: Cracks In The Bearish Trade